Loading
companiesCompany
Kymera Therapeutics
Oral degrader company, mostly immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers.
Overview
Kymera Therapeutics, based in Watertown, Massachusetts, and listed as KYMR, is an oral protein degrader company focused mostly on immunology, whose CDK2 molecular-glue degrader was optioned by Gilead in 2026 for CCNE1-driven cancers. Gilead paid 40 million dollars for an option in June 2025 and exercised it for 45 million dollars in April 2026 on the preclinical CDK2 glue degrader KT-200, aimed at CCNE1-amplified tumours and resistance to CDK4/6 inhibitors, while Kymera's own clinical pipeline against IRAK4, STAT6 and TYK2 is immunological. OnCo links it to ovarian and HR-positive breast cancer, to PROTACs and molecular glues and glue discovery platforms, to CDK4/6 as a target, to Gilead, and to ideas including glues that break the MYC-MAX partnership. The undruggable drivers are the bottleneck it bears on. Whether CDK2 degradation is tolerable is the open question.
Similar pages
- CompanyMonte Rosa Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, An open degrader consortium against every undruggable driver transcription factor, Design protein degraders small enough to get into the brain.
- CompanyC4 Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Molecular glue discovery platforms.
- CompanyNurix Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it, Design protein degraders small enough to get into the brain, Use antibodies to deliver protein-destroying drugs into the right cells.
- Key paperDrugging the 'undruggable' cancer targets
Shares Find E3 ligases that only tumours have, and build degraders around them, Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Use antibodies to deliver protein-destroying drugs into the right cells.
- CompanyArvinas
Shares An open degrader consortium against every undruggable driver transcription factor, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer.
- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Molecular glue discovery platforms, The undruggable drivers, PROTACs & molecular glues (targeted protein degradation).
- TechnologyDegrader-antibody conjugate (DAC)
Shares Use antibodies to deliver protein-destroying drugs into the right cells, Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
- PersonAaron Ciechanover
Shares Molecular glue discovery platforms, PROTACs & molecular glues (targeted protein degradation).
cancers
fronts
technologies
targets
companies
ideas
An open degrader consortium against every undruggable driver transcription factorDesign protein degraders small enough to get into the brainFind E3 ligases that only tumours have, and build degraders around themMolecular glues that break the MYC-MAX partnershipScreen glue-like compounds against every cancer cell line and publish itUse antibodies to deliver protein-destroying drugs into the right cells